GeminiBio Launches aiMOS, AI-Enabled Media Optimisation Service for Cell Therapy Manufacturing
Published: 16 Mar 2026
Author: Precedence Research
Chief Scientific Officer at GeminiBio, Robert Perry, stated that as cell therapies advance, customers are looking for partners who provide both high-quality raw materials and pathways to process optimisation.
aiMOS builds an industry-leading position in human AB serum and expands its ability to help developers improve CQAs and reduce manufacturing risk, along with clinical and commercial success.
PhD, co-founder, Tolemy Bio, Alex Ward, given his statement,” By applying causal AI modelling to a cell’s metabolic and behavioural fingerprints, our platform can identify the exact levers that drive cell therapy performance, potency and yield. With that information, we can then predict the ideal supplement composition and concentrations to specifically enhance cell performance.”
According to Toward Healthcare, the Cell Culture Supplements Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 3.15 billion in 2026 to approximately USD 9.71 billion by 2035, representing a compound annual growth rate (CAGR) of 13.32% from 2026 to 2035. The aiMOS builds on a foundation by shifting from general supplementation to data-driven, process-specific media optimisation that enhances a customer’s satisfaction unleash targeted cell therapy performance improvements.
About GeminiBio
Gemini Bioproducts, LLC, a biopharma and advanced therapy material, and BelHealth Investment Partners LLC, a portfolio company, announced the launch of aiMOS (Artificial Intelligence Media Optimisation Service). This service leverages artificial intelligence/machine learning and multi-omics data to design custom media supplements that help to improve the performance, consistency, and scalability of cell therapy manufacturing. Developed in collaboration with Tolemy Bio, aiMOS is designed to help cell therapy innovators enhance critical quality attributes (CQAs), increase manufacturing efficiency, and reduce overall cost.
GeminiBio provide advanced therapy companies and focuses on the research and production of mRNA, AAV, monoclonal antibodies, and cell therapy technologies. It has been widely adopted as a key supplement in cell-therapy workflows, supporting robust immune-cell expansion in both terms clinical and commercial manufacturing.
A recent report by Toward Healthcare highlights that the Cell Culture Supplements Market is accelerating the development of life-enhancing biotherapeutics by streamlining and improving cell culture and process liquid manufacturing workflows.